

Mattia Capulli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7395893/publications.pdf>

Version: 2024-02-01

41
papers

1,263
citations

393982

19
h-index

454577

30
g-index

41
all docs

41
docs citations

41
times ranked

2350
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined administration of a small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis. <i>Cancer Letters</i> , 2020, 488, 27-39.	3.2	15
2	<scp>CRELD2</scp> Is a Novel <scp>LRP1</scp> Chaperone That Regulates Noncanonical <scp>WNT</scp> Signaling in Skeletal Development. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1452-1469.	3.1	12
3	Extra-skeletal manifestations in mice affected by Clcn7-dependent autosomal dominant osteopetrosis type 2 clinical and therapeutic implications. <i>Bone Research</i> , 2019, 7, 17.	5.4	12
4	Notch2 pathway mediates breast cancer cellular dormancy and mobilisation in bone and contributes to haematopoietic stem cell mimicry. <i>British Journal of Cancer</i> , 2019, 121, 157-171.	2.9	59
5	Testing the Cre-mediated genetic switch for the generation of conditional knock-in mice. <i>PLoS ONE</i> , 2019, 14, e0213660.	1.1	5
6	Osteoblasts Regulate Angiogenesis in Response to Mechanical Unloading. <i>Calcified Tissue International</i> , 2019, 104, 344-354.	1.5	12
7	A Complex Role for Lipocalin 2 in Bone Metabolism: Global Ablation in Mice Induces Osteopenia Caused by an Altered Energy Metabolism. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1141-1153.	3.1	36
8	TRAF2 in osteotropic breast cancer cells enhances skeletal tumour growth and promotes osteolysis. <i>Scientific Reports</i> , 2018, 8, 39.	1.6	30
9	RNA interference therapy for autosomal dominant osteopetrosis type 2. Towards the preclinical development. <i>Bone</i> , 2018, 110, 343-354.	1.4	20
10	The Vicious Cycle of Breast Cancer-Induced Bone Metastases, a Complex Biological and Therapeutic Target. <i>Current Molecular Biology Reports</i> , 2018, 4, 123-131.	0.8	5
11	Regulation of breast cancer induced bone disease by cancer-specific IKK β . <i>Oncotarget</i> , 2018, 9, 16134-16148.	0.8	6
12	Non-conventional role of haemoglobin beta in breast malignancy. <i>British Journal of Cancer</i> , 2017, 117, 994-1006.	2.9	31
13	Interleukin-1 β , lipocalin 2 and nitric oxide synthase 2 are mechano-responsive mediators of mouse and human endothelial cell-osteoblast crosstalk. <i>Scientific Reports</i> , 2016, 6, 29880.	1.6	35
14	Effective Small Interfering RNA Therapy to Treat CLCN7-dependent Autosomal Dominant Osteopetrosis Type 2. <i>Molecular Therapy - Nucleic Acids</i> , 2015, 4, e248.	2.3	21
15	Biotechnological approach for systemic delivery of membrane Receptor Activator of NF- κ B Ligand (RANKL) active domain into the circulation. <i>Biomaterials</i> , 2015, 46, 58-69.	5.7	23
16	The β 1 binding domain of chondroadherin inhibits breast cancer-induced bone metastases and impairs primary tumour growth: A preclinical study. <i>Cancer Letters</i> , 2015, 358, 67-75.	3.2	13
17	Lipocalin 2: A New Mechanoresponding Gene Regulating Bone Homeostasis. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 357-368.	3.1	76
18	Osteoblast and osteocyte: Games without frontiers. <i>Archives of Biochemistry and Biophysics</i> , 2014, 561, 3-12.	1.4	266

#	ARTICLE	IF	CITATIONS
19	The C-Terminal Domain of Chondroadherin: A New Regulator of Osteoclast Motility Counteracting Bone Loss. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1833-1846.	3.1	17
20	Generation and culture of osteoclasts. <i>BoneKEy Reports</i> , 2014, 3, 570.	2.7	87
21	Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression. <i>BMC Cancer</i> , 2014, 14, 154.	1.1	92
22	Generation of the first autosomal dominant osteopetrosis type II (ADO2) disease models. <i>Bone</i> , 2014, 59, 66-75.	1.4	36
23	Proline/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1912-1924.	3.1	21
24	NHERF1 acts as a molecular switch to program metastatic behavior and organotropism via its PDZ domains. <i>Molecular Biology of the Cell</i> , 2012, 23, 2028-2040.	0.9	19
25	Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 2387-2398.	3.1	24
26	Mechanisms inducing low bone density in duchenne muscular dystrophy in mice and humans. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 1891-1903.	3.1	116
27	The N-terminal domain of the bone protein PProline/arginine-rich End Leucine-rich repeat Protein (PRELP) impairs osteoclast formation by a new mechanism inhibiting NF- κ B signaling. <i>Bone</i> , 2010, 46, S64-S65.	1.4	0
28	MECHANISMS INDUCING LOW BONE DENSITY IN DUCHENNE MUSCULAR DYSTROPHY. <i>Bone</i> , 2010, 46, S79-S80.	1.4	1
29	The glycosaminoglycan-binding domain of PRELP acts as a cell type-specific NF- κ B inhibitor that impairs osteoclastogenesis. <i>Journal of Cell Biology</i> , 2009, 187, 669-683.	2.3	72
30	Global transcriptome analysis in mouse calvarial osteoblasts highlights sets of genes regulated by modeled microgravity and identifies a α -mechanoresponsive osteoblast gene signature. <i>Journal of Cellular Biochemistry</i> , 2009, 107, 240-252.	1.2	63
31	β 2-Arrestin2 Regulates RANKL and Ephrins Gene Expression in Response to Bone Remodeling in Mice. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 775-784.	3.1	37
32	The glycosaminoglycan-binding domain of PRELP acts as a cell type-specific NF- κ B inhibitor that impairs osteoclastogenesis. <i>Journal of Experimental Medicine</i> , 2009, 206, i32-i32.	4.2	0
33	P50. Osteotropic poly(d,l-lactide-co-glycolide)-alendronate nanoparticles for the treatment of bone cancer. <i>Cancer Treatment Reviews</i> , 2008, 34, 38.	3.4	0
34	Involvement of the co-receptor RAMP2 in the progression of breast cancer-induced osteolytic lesions. <i>Bone Abstracts</i> , 0, , .	0.0	0
35	Multidisciplinary studies of ancient calcified tissues: renal stones from mummies. <i>Bone Abstracts</i> , 0, , .	0.0	0
36	multidisciplinary studies of ancient calcified tissues II: contents from Egyptian canopic jars. <i>Bone Abstracts</i> , 0, , .	0.0	0

#	ARTICLE	IF	CITATIONS
37	Small interfering RNAs as an innovative therapeutic approach for the autosomal dominant osteopetrosis type 2 (ADO2). Bone Abstracts, 0, , .	0.0	1
38	The critical biomechanical role of Lipocalin 2 in the crosstalk between endothelium and osteoblasts in unloading conditions.. Bone Abstracts, 0, , .	0.0	0
39	Connecting the dots between bone and energy metabolism: the role of Lipocalin 2. Bone Abstracts, 0, , .	0.0	0
40	Storage disease and neurological phenotype in autosomal dominant osteopetrosis type 2 (ADO2). A preclinical study. Bone Abstracts, 0, , .	0.0	0
41	The role of Creld2 in skeletal development and homeostasis. Bone Abstracts, 0, , .	0.0	0